[18F]Tetrafluoroborate([18F]Tetrafluoroborate) - 药物靶点：NIS_在研适应症：子宫内膜癌，多发性骨髓瘤，子宫内膜透明细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

NIS

作用机制

NIS调节剂(solute carrier family 5 member 5 modulators)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病心血管疾病+ [2]

在研适应症

子宫内膜癌多发性骨髓瘤子宫内膜透明细胞癌+ [9]

非在研适应症-

原研机构

Mayo Clinic

在研机构

National Cancer Institute

Mayo Clinic

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 [18F]Tetrafluoroborate 相关的临床试验

NCT03120624 / Active, not recruiting临床1期IIT

Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer

This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.

开始日期2017-09-15

申办/合作机构

Mayo Clinic

[+1]

NCT02907073 / Terminated临床1/2期IIT

First In-human PET Imaging Studies With NIS Reporter [18F]BF4

The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).

开始日期2016-09-01

申办/合作机构

Mayo Clinic

ISRCTN75827286 / Completed临床1期

A phase I trial of [18F]-tetrafluoroborate in patients with primary thyroid cancer or salivary cancer to study biodistribution and uptake in tumours and normal NIS expressing tissue

开始日期2015-09-14

申办/合作机构

King's College London

100 项与 [18F]Tetrafluoroborate 相关的临床结果

登录后查看更多信息

100 项与 [18F]Tetrafluoroborate 相关的转化医学

登录后查看更多信息

100 项与 [18F]Tetrafluoroborate 相关的专利（医药）

登录后查看更多信息

2

项与 [18F]Tetrafluoroborate 相关的文献（医药）

2014-01-01·Physical Chemistry Chemical Physics2区 · 化学

Introducing manganese complexes as redox mediators for dye-sensitized solar cells

2区 · 化学

Article

作者: Udo Bach ; Ishanie Rangeeka Perera ; Akhil Gupta ; Wanchun Xiang ; Torben Daeneke ; Leone Spiccia ; C. André Ohlin ; Richard A. Evans

The abundance and low toxicity of manganese have led us to explore the application of manganese complexes as redox mediators for dye sensitized solar cells (DSCs), a promising solar energy conversion technology which mimics some of the key processes in photosynthesis during its operation. In this paper, we report the development of a DSC electrolyte based on the tris(acetylacetonato)manganese(iii)/(iv), [Mn(acac)3](0/1+), redox couple. PEDOT-coated FTO glass was used as a counter electrode instead of the conventionally used platinum. The influence of a number of device parameters on the DSC performance was studied, including the concentration of the reduced and oxidized mediator species, the concentration of specific additives (4-tert-butylpyridine, lithium tetrafluoroborate, and chenodeoxycholic acid) and the thickness of the TiO2 working electrode. These studies were carried out with a new donor-π-acceptor sensitizer K4. Maximum energy conversion efficiencies of 3.8% at simulated one Sun irradiation (AM 1.5 G; 1000 W m(-2)) with an open circuit voltage (VOC) of 765 mV, a short-circuit current (JSC) of 7.8 mA cm(-2) and a fill factor (FF) of 0.72 were obtained. Application of the commercially available MK2 and N719 sensitizers resulted in an energy conversion efficiency of 4.4% with a VOC of 733 mV and a JSC of 8.6 mA cm(-2) for MK2 and a VOC of 771 mV and a JSC of 7.9 mA cm(-2) for N719. Both dyes exhibit higher incident photon to current conversion efficiencies (IPCEs) than K4.

2011-07-14·The Journal of Physical Chemistry B3区 · 化学

Thermodynamic Behavior of the Binaries 1-Butylpyridinium Tetrafluoroborate with Water and Alkanols: Their Interpretation Using ¹H NMR Spectroscopy and Quantum-Chemistry Calculations

3区 · 化学

Article

作者: Penco, Eduvigis ; Vreekamp, Remko ; Fernández, Luís ; Ortega, Juan ; Palomar, José ; Castellano, Desire ; Espiau, Fernando

Here we present experimental data of different properties for a set of binary mixtures composed of water or alkanols (methanol to butanol) with an ionic liquid (IL), butylpyridinium tetrafluoroborate [bpy][BF(4)]. Solubility data (x(IL),T) are presented for each of the mixtures, including water, which is found to have a small interval of compositions in IL, x(IL), with immiscibility. In each case, the upper critical solubility temperature (UCST) is determined and a correlation was observed between the UCST and the nature of the compounds in the mixtures. Miscibility curves establish the composition and temperature intervals where thermodynamic properties of the mixtures, such as enthalpies H(m)(E) and volumes V(m)(E), can be determined. Hence, at 298.15 and 318.15 K these can only be found with the first four alkanols. All mixing properties are correlated with a suitable equation ξ (x(IL),T,Y(m)(E) = 0. An analysis on the influence of the temperature in the properties is shown, likewise a comparison between the results obtained here and those of analogous mixtures, discussing the position of the -CH(3) group in the pyridinic ring. The (1)H NMR spectra are determined to analyze the molecular interactions present, especially those due to hydrogen bonds. Additional information about the molecular interactions and their influence on the mixing properties is obtained by quantum chemistry calculations.

100 项与 [18F]Tetrafluoroborate 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫内膜癌	临床2期	-	Mayo Clinic	-
多发性骨髓瘤	临床2期	-	Mayo Clinic	-
子宫内膜透明细胞癌	临床1期	美国	National Cancer Institute	2017-09-15
子宫内膜样腺癌	临床1期	美国	National Cancer Institute	2017-09-15
子宫内膜混合上皮癌	临床1期	美国	National Cancer Institute	2017-09-15
子宫内膜未分化癌	临床1期	美国	National Cancer Institute	2017-09-15
转移性子宫内膜恶性肿瘤	临床1期	美国	National Cancer Institute	2017-09-15
复发性子宫体肉瘤	临床1期	美国	National Cancer Institute	2017-09-15
子宫浆液性癌	临床1期	美国	National Cancer Institute	2017-09-15
子宫腺癌	临床1期	美国	National Cancer Institute	2017-09-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03120624 (Voyager-V1, CTgov)	临床1期	子宫体癌 \| 子宫内膜样腺癌 \| 复发性子宫体肉瘤 \| 子宫内膜透明细胞癌 \| 子宫内膜混合上皮癌 \| 子宫浆液性癌 \| 转移性子宫内膜恶性肿瘤 \| 子宫内膜未分化癌 \| 复发性子宫内膜癌 \| 子宫腺癌	34	TFB+technetium Tc-99m sodium pertechnetate+fluorine F18 tetrafluoroborate+VSV-hIFNbeta-NIS (Cohort A Dose Level 1)	範觸構壓膚範夢遞醖淵(餘膚選願簾壓鑰齋顧膚) = 膚襯鑰鹽願壓繭願範餘衊遞糧壓襯糧製淵鹽醖 (簾顧醖夢壓繭壓範範鬱, 獵顧淵選窪淵遞觸觸襯 ~ 積範製構網顧鬱簾觸醖) 更多	-	2024-10-29
				TFB+technetium Tc-99m sodium pertechnetate+fluorine F18 tetrafluoroborate+VSV-hIFNbeta-NIS (Cohort A Dose Level 2)	範觸構壓膚範夢遞醖淵(餘膚選願簾壓鑰齋顧膚) = 憲築襯鹽憲蓋衊齋蓋遞衊遞糧壓襯糧製淵鹽醖 (簾顧醖夢壓繭壓範範鬱, 衊鏇範繭膚製蓋鬱遞顧 ~ 窪襯醖網廠窪構襯夢齋) 更多
NCT02907073 (CTgov)	临床1/2期	子宫内膜癌 \| 多发性骨髓瘤	8	BF4 (Healthy Volunteers)	壓齋鬱襯獵廠鏇範壓憲(夢網糧襯蓋蓋繭膚構艱) = 襯積膚憲衊艱觸廠鹽網糧襯窪壓艱夢餘網範艱 (窪鏇網遞窪築膚顧壓鬱, 選齋繭艱鏇構簾窪積艱 ~ 積淵衊製簾壓衊夢鹽憲) 更多	-	2019-05-17
				BF4 (Myeloma Patients)	選衊夢鬱襯餘製憲醖網(夢憲鏇夢糧鹹憲鬱積簾) = 構窪衊糧糧窪襯糧簾窪蓋遞鹹廠餘鬱選膚鬱壓 (窪遞膚築廠鏇範鹹鑰艱, 窪鏇淵窪鹹壓醖範憲齋 ~ 範獵構鏇顧範鹹鏇窪獵) 更多